Across TCGA pan-cancer cohorts, TMEM255B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM255B data layer compared with 28 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM255B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM255B expression acts as an unfavorable survival marker.
BLCA, KIRC, and UCEC are the cancer types where TMEM255B Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.